Web Desc
Bioterrorism and Emerging Infectious Diseases: Antimicrobials, Therapeutics and Immune-Modulators
joint with Rational Design of Vaccines and Immunotherapeutics
Organizer(s): Connie Schmaljohn and Michael Buchmeier
Date: January 06 - 11, 2004
Location: Keystone Resort, Keystone, CO, USA
Supported by Keystone Symposia
For important information on the coronavirus, please click here
Summary of Meeting:
The threats of bioterrorism and emerging infectious diseases have captured the attention of both the scientific and lay communities. Deliberate release of anthrax spores in the U.S. fostered the introduction of homeland security measures worldwide, and led to new efforts to predict the occurrence of and prepare for the appearance of other biothreats. In addition to the use of known pathogens for bioterrorism, there is concern that technological advances in genetic engineering might lead to the creation of novel threat agents for which we are completely unprepared. Not only could such intentionally released pathogens wreak havoc on global health and agricultural systems and economies, so could new naturally occurring disease agents. The recent emergence of SARS and its rapid spread throughout the world is an excellent example of how a novel and unexpected pathogen can quickly overwhelm health care resources. This meeting will address many issues related to preventing and treating diseases caused by exposure to natural or genetically engineered pathogens. Experts in each field will present state-of-the-art research results in plenary talks. Workshops will allow a closer interaction of scientists from many disciplines, who share common goals of understanding and combating biothreats. The Keystone Symposium format offers ample time for discussion and small group meetings and is an ideal means for investigators to gain up to date information on this important topic.
Discounted Abstract Deadline: September 15 2003
Discounted Registration Deadline: November 6 2003
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 U13 AI60000-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Tuesday, January 06 | 3:00PM - 7:00PM
Registration
Room: Longs Foyer


Tuesday, January 06 | 6:15PM - 7:15PM
Refreshments
Room: Longs Foyer


Tuesday, January 06 | 7:15PM - 7:30PM
Orientation
Room: Grays Peak 1-3


Tuesday, January 06 | 7:30PM - 9:30PM
Keynote Addresses (Joint)
Room: Grays Peak 1-3

Speaker 1 of 4
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Tuesday, January 06 | 7:30PM - 9:30PM
Keynote Addresses (Joint)
Room: Grays Peak 1-3

Speaker 2 of 4
Julie L. Gerberding, Merck & Co., USA
Preparing for 'The New Normal': Innovations in Countermeasures to Combat Public Health Threats

Tuesday, January 06 | 7:30PM - 9:30PM
Keynote Addresses (Joint)
Room: Grays Peak 1-3

Speaker 3 of 4
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

Tuesday, January 06 | 7:30PM - 9:30PM
Keynote Addresses (Joint)
Room: Grays Peak 1-3

Speaker 4 of 4
Stanley A. Plotkin, Vaxconsult, LLC, USA
Rational Design of Vaccines: Revolution or Evolution?

Wednesday, January 07 | 7:00AM - 8:00AM
Breakfast
Room: Longs Peak


Wednesday, January 07 | 8:00AM - 11:00AM
Infectious Clone Technology: What Have We Learned So Far?
Room: Grays Peak 3

Speaker 1 of 5
* Michael J. Buchmeier, University of California Irvine, USA

Wednesday, January 07 | 8:00AM - 11:00AM
Infectious Clone Technology: What Have We Learned So Far?
Room: Grays Peak 3

Speaker 2 of 5
Yoshihiro Kawaoka, University of Wisconsin / University of Tokyo, USA
The Power of Reverse Genetics

Wednesday, January 07 | 8:00AM - 11:00AM
Infectious Clone Technology: What Have We Learned So Far?
Room: Grays Peak 3

Speaker 3 of 5
Adolfo García-Sastre, Mount Sinai School of Medicine, USA
Type I Interferon Antagonists of RNA Viruses: Novel Targets for Attenuation in Live Virus Vaccines

Wednesday, January 07 | 8:00AM - 11:00AM
Infectious Clone Technology: What Have We Learned So Far?
Room: Grays Peak 3

Speaker 4 of 5
Juan Carlos de la Torre, The Scripps Research Institute, USA
Arenavirus Reverse Genetics: Implications for Novel Antiviral Strategies

Wednesday, January 07 | 8:00AM - 11:00AM
Infectious Clone Technology: What Have We Learned So Far?
Room: Grays Peak 3

Speaker 5 of 5
Ute Stroeher, Canadian Science Centre for Human and Animal Health, Canada
Reverse Genetics Systems for High-Containment Viruses: Development and Potential Use

Wednesday, January 07 | 8:00AM - 11:00AM
T Cell Differentiation and Memory; Pathways of Antigen Proc
essing, Co-Stimulation. Session Sponsored in Part by BD Technologies.
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 1 of 4
* Peter C. Doherty, University of Melbourne, Australia
Naïve and Memory T Cells in Viral Infections


Wednesday, January 07 | 8:00AM - 11:00AM
T Cell Differentiation and Memory; Pathways of Antigen Proc
essing, Co-Stimulation. Session Sponsored in Part by BD Technologies.
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 2 of 4
Susan M. Kaech, The Salk Institute, USA
Pathways of Memory CD8 T Cell Differentiation


Wednesday, January 07 | 8:00AM - 11:00AM
T Cell Differentiation and Memory; Pathways of Antigen Proc
essing, Co-Stimulation. Session Sponsored in Part by BD Technologies.
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 3 of 4
Susan L. Swain, University of Massachusetts Medical School, USA
Regulation of CD4 T Cell Memory Generation


Wednesday, January 07 | 8:00AM - 11:00AM
T Cell Differentiation and Memory; Pathways of Antigen Proc
essing, Co-Stimulation. Session Sponsored in Part by BD Technologies.
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 4 of 4
Jay A. Berzofsky, NCI, National Institutes of Health, USA
Role of IL-15 in CD8+ T Cell Memory and Avidity Maturation


Wednesday, January 07 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Foyer


Wednesday, January 07 | 11:00AM - 1:00PM
Poster Setup
Room: Longs Peak


Wednesday, January 07 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs Peak


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 1 of 8
* Paul F. Bates, University of Pennsylvania School of Medicine, USA

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 2 of 8
Andrea F. Bertolotti-Ciarlet, University of Pennsylvania, USA
Cellular Processing and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus Glycoproteins

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 3 of 8
Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Use of alpha-Dystroglycan as a Receptor by the Arenaviruses

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 4 of 8
David M. Koelle, University of Washington, USA
Intradermal Vaccinia and Skin-Homing T-Cells

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 5 of 8
Mansour Mohamadzadeh, Tulane Medical School, USA
Targeting HCV NS3-NS4A to Dendritic Cells (DC) via DC-Binding Peptides Induces Potent T Cell Immunity in vivo

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 6 of 8
Onesmo Mpanju, U.S. Food and Drug Administration, USA
Identification of Critical Amino Acid Residues on Ebola Virus Glycoprotein Required for Cell Entry

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 7 of 8
Ted C. Pierson, NIAID, National Institutes of Health, USA
Development of Novel Reporter Viruses for the Study of West Nile Virus Entry and its Inhibition

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Pathogen Receptor Interactions
Room: Grays Peak 3

Speaker 8 of 8
Christopher Premanandan, Ohio State University College of Veterinary Medicine, USA
Interactions of Bacillus anthracis Exotoxins and Cellular Receptors within the Phagolysosome

Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 9
* John A. Mikszta, BD Technologies, USA


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 9
* Peter Daddona, Zosano Pharma , Inc., USA


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 9
Catharine M. Bosio, NIAID, National Institutes of Health, USA
Immunogenicity and Protective Efficacy of Liposome-Based Mucosal Vaccines Against Y. pestis


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 9
Sophie Chabot, USA
A Novel Intranasal Proteosome-Based Measles Vaccine Induces Neutralizing Antibody Responses in Mice


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 5 of 9
Lakshmi Krishnan, Institute for Biological Sciences, Canada
Delivery of Antigen in Archaeosome Adjuvant Sustains Antigen Presentation and CD8+ CTL Memory in vivo


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 6 of 9
Thomas M. Luby, Abraxis BioScience, USA
Generation of Immune Responses by Immunization with Plasmid DNA Encapsulated in Poly (Lactide-Co-Glycolide) Microparticles is Enhanced by in vivo Electroporation


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 7 of 9
Robert G. Ulrich, Research Institute of Infectious Diseases, USA
Evaluation of New Delivery Devices Targeting the Skin with Recombinant Protein Vaccines


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 8 of 9
Sarah M. Hook, University of Otago, New Zealand
A Formulation Approach to Improving Vaccine Innunogenicity


Wednesday, January 07 | 2:00PM - 4:00PM
Workshop 1: Skin and Mucosal Delivery of Vaccines
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 9 of 9
James Matriano, ALZA Corporation, USA
A Rapid and Efficient Skin Patch Technology for Vaccine Delivery


Wednesday, January 07 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Longs Foyer


Wednesday, January 07 | 5:00PM - 6:15PM
Genomics and Proteomics: Discovery of Antigens and Immune Mo
dulators (Joint)

Room: Grays Peak 1-2

Speaker 1 of 3
* Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA

Wednesday, January 07 | 5:00PM - 6:15PM
Genomics and Proteomics: Discovery of Antigens and Immune Mo
dulators (Joint)

Room: Grays Peak 1-2

Speaker 2 of 3
Peter L. Andersen, Statens Serum Institut, Denmark
Post Genomic Insights for the Design of TB Vaccines for Pre- and Post-Infection Administration

Wednesday, January 07 | 5:00PM - 6:15PM
Genomics and Proteomics: Discovery of Antigens and Immune Mo
dulators (Joint)

Room: Grays Peak 1-2

Speaker 3 of 3
Daniel J. Carucci, Foundation for the National Institutes of Health, USA
Identification of Malaria Vaccine Antigens by Proteomics and Incorporation into Molecular Vaccine Development

Wednesday, January 07 | 6:15PM - 7:30PM
Genomic Responses to Infection (Joint)
Room: Grays Peak 1-2

Speaker 1 of 3
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Wednesday, January 07 | 6:15PM - 7:30PM
Genomic Responses to Infection (Joint)
Room: Grays Peak 1-2

Speaker 2 of 3
Alan Aderem, Center for Infectious Disease Research, USA
Large Scale Approaches to Dissecting the Innate Immune Response

Wednesday, January 07 | 6:15PM - 7:30PM
Genomic Responses to Infection (Joint)
Room: Grays Peak 1-2

Speaker 3 of 3
David A. Relman, Stanford University, USA
How the Host Classifies Systemic Infection

Wednesday, January 07 | 7:30PM - 8:30PM
Social Hour
Room: Longs Peak


Wednesday, January 07 | 7:30PM - 10:00PM
Poster Session 1
Room: Longs Peak


Thursday, January 08 | 7:00AM - 8:00AM
Breakfast
Room: Longs Peak


Thursday, January 08 | 8:00AM - 11:00AM
New Information on Antiviral Mechanism of Action
Room: Grays Peak 3

Speaker 1 of 5
* Robert M. Krug, University of Texas at Austin, USA

Thursday, January 08 | 8:00AM - 11:00AM
New Information on Antiviral Mechanism of Action
Room: Grays Peak 3

Speaker 2 of 5
Raul Andino, University of California, San Francisco, USA
The Fine Line Between Genetic Plasticity and Mutagenesis

Thursday, January 08 | 8:00AM - 11:00AM
New Information on Antiviral Mechanism of Action
Room: Grays Peak 3

Speaker 3 of 5
Erik De Clercq, Katholieke Universiteit Leuven, Belgium
Therapeutic Potential of Nucleoside/Nucleotide Analogs Against Poxvirus Infections

Thursday, January 08 | 8:00AM - 11:00AM
New Information on Antiviral Mechanism of Action
Room: Grays Peak 3

Speaker 4 of 5
Marc S. Collett, Viropharma, Inc., USA
Antiviral Drugs for Virological Threats of Bioterrorism and Emerging Diseases

Thursday, January 08 | 8:00AM - 11:00AM
New Information on Antiviral Mechanism of Action
Room: Grays Peak 3

Speaker 5 of 5
Karl Y. Hostetler, University of California, San Diego, USA
Synthesis and Evaluation of Orally Active Drugs for Orthopoxvirus Infections

Thursday, January 08 | 8:00AM - 11:00AM
Regulating Immune Responses: New Insights into T Helper Cell
s
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 1 of 4
Kevin J. Maloy, University of Oxford, UK
Control of Intestinal Inflammation by Regulatory T Cells


Thursday, January 08 | 8:00AM - 11:00AM
Regulating Immune Responses: New Insights into T Helper Cell
s
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 2 of 4
Jeffrey A. Bluestone, University of California, San Francisco, USA
Pathways to Tolerance in Autoimmunity


Thursday, January 08 | 8:00AM - 11:00AM
Regulating Immune Responses: New Insights into T Helper Cell
s
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 3 of 4
* Robert A. Seder, NIAID, National Institutes of Health, USA
Distinct Lineages of Th1 Memory Cells have Differential Survival in vivo:
Implications for Vaccine Development Against Diseases Requiring Th1 Responses


Thursday, January 08 | 8:00AM - 11:00AM
Regulating Immune Responses: New Insights into T Helper Cell
s
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 4 of 4
Ronald N. Germain, NIAID, National Institutes of Health, USA
Self-Recognition and the Foreign Antigen Sensitivity of Naïve T Cells


Thursday, January 08 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Foyer


Thursday, January 08 | 11:00AM - 1:00PM
Poster Setup
Room: Longs Peak


Thursday, January 08 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs Peak


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 1 of 7
* Colleen B. Jonsson, University of Louisville, USA

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 2 of 7
Robert M. Krug, University of Texas at Austin, USA
Special Lecture: Novel Targets for Antivirals: The Multiple Functional Domains of the NS1 Proteins of Human Influenza Viruses

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 3 of 7
Jeffrey B. Arterburn, New Mexico State University, USA
New Synthetic Nucleoside Antivirals for Hantavirus

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 4 of 7
Frank Alexander Hamill, S.W. Foundation Biomedical Research, USA
Anti-Ebola, Anti-Lassa and Anti-SARS CoV Activity of Antimicrobial Natural Product Chemicals from Rubus apetalus

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 5 of 7
Lisa E. Hensley, NIAID, National Institutes of Health, USA
Evaluation of Interferon-beta as a Therapeutic Treatment for Ebola Hemorrhagic Fever in Nonhuman Primates

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 6 of 7
Benjamin W. Neuman, The Scripps Research Institute, USA
Arenavirus Inside Out: Cryo-EM Structural Studies of Three Arenaviruses

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Novel Approaches to Therapeutics
Room: Grays Peak 3

Speaker 7 of 7
Tibor P. Keler, Celldex Therapeutics, Inc., USA
Development of Fully Human Antibody Against Anthrax Protective Antigen

Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 7
Martin Friede, World Health Organization, Switzerland
Aerosol Delivery of Vaccines: The Measles Aerosol Project


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 7
Yukio Koide, Hamamatsu University School of Medicine, Japan
Induction of Protective Cellular Immunity Against Mycobacterium tuberculosis by Recombinant Attenuated Self-Destructing Listeria monocytogenes Strains Harboring Eukaryotic Expression Plasmids for Ag85 complex and MPB/MPT51


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 7
Sandra Verhaagh, Crucell Holland BV, Netherlands
Studies Towards an Adenovirus-Based Malaria Vaccine


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 7
Carmel B. Stober, University of Cambridge, UK
From Genomes to Vaccines for leishmaniasis


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 5 of 7
Erik Rollman, BioArctic, Sweden
HPV-16 L1 Genes with Inactivated Negative RNA Elements Induce Potent Immune Responses


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 6 of 7
Maria J. Gonzalez, The Scripps Research Institute, USA
Induction of T-Cell Immunity by a Plant Virus Vaccine


Thursday, January 08 | 2:00PM - 4:00PM
Workshop 2: Vaccines for Developing Countries: Diseases and
Technologies
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 7 of 7
Martin Friede, World Health Organization, Switzerland
Vaccines and Technologies for Resource-Poor Settings


Thursday, January 08 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Longs Foyer


Thursday, January 08 | 5:00PM - 7:00PM
Impact of Receptor Binding
Room: Grays Peak 3

Speaker 1 of 3
* John A. T. Young, F.Hoffmann-La Roche Ltd, Switzerland
Anthrax Toxin-Receptor Interactions

Thursday, January 08 | 5:00PM - 7:00PM
Impact of Receptor Binding
Room: Grays Peak 3

Speaker 2 of 3
Paul F. Bates, University of Pennsylvania School of Medicine, USA
Interaction of Ebola Virus Glycoproteins with Host Factors

Thursday, January 08 | 5:00PM - 7:00PM
Impact of Receptor Binding
Room: Grays Peak 3

Speaker 3 of 3
Kathryn V. Holmes, University of Colorado School of Medicine, USA
Determinants of Coronavirus Host Ranges

Thursday, January 08 | 5:00PM - 7:00PM
Innate Immunity: How to Harness or Suppress It
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 4
* Eyal Raz, University of California, San Diego, USA


Thursday, January 08 | 5:00PM - 7:00PM
Innate Immunity: How to Harness or Suppress It
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 4
Peter Aaby, Statens Serum Institut, Denmark
Non-Targeted Effects of Vaccination: Immune Effects and Impact on Additionally Administered Vaccines


Thursday, January 08 | 5:00PM - 7:00PM
Innate Immunity: How to Harness or Suppress It
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 4
Dennis M. Klinman, U.S. Food and Drug Administration, USA
Progress Towards Understanding the Properties of DNA


Thursday, January 08 | 5:00PM - 7:00PM
Innate Immunity: How to Harness or Suppress It
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 4
Heather L. Davis, Pfizer Inc., Canada
Use of CpG TLR9 Agonist as a Vaccine Adjuvant by Parental or Mucosal Routes


Thursday, January 08 | 7:00PM - 8:00PM
Social Hour
Room: Longs Peak


Thursday, January 08 | 7:30PM - 10:00PM
Poster Session 2
Room: Longs Peak


Friday, January 09 | 7:00AM - 8:00AM
Breakfast
Room: Longs Peak


Friday, January 09 | 8:00AM - 11:00AM
SARS: The First Year
Room: Grays Peak 3

Speaker 1 of 5
* Peter B. Jahrling, National Institutes of Health, USA

Friday, January 09 | 8:00AM - 11:00AM
SARS: The First Year
Room: Grays Peak 3

Speaker 2 of 5
Frank Plummer, Public Health Agency of Canada, Canada
SARS: Lessons Learned in Canada

Friday, January 09 | 8:00AM - 11:00AM
SARS: The First Year
Room: Grays Peak 3

Speaker 3 of 5
Ralph S. Baric, University of North Carolina at Chapel Hill, USA
Reverse Genetics with a Full-Length Infectious cDNA of the Severe Acute Respiratory Disease Syndrome Coronavirus

Friday, January 09 | 8:00AM - 11:00AM
SARS: The First Year
Room: Grays Peak 3

Speaker 4 of 5
Thomas G. Ksiazek, Centers for Disease Control, USA
Identification of a New Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)

Friday, January 09 | 8:00AM - 11:00AM
SARS: The First Year
Room: Grays Peak 3

Speaker 5 of 5
Mark R. Denison, Vanderbilt University Medical Center, USA
SARS Coronavirus Genetics and Replication

Friday, January 09 | 8:00AM - 11:00AM
Delivery Systems and Mucosal Immunization
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 4
Kam W. Leong, Johns Hopkins University in Singapore, Singapore
Formulation and Delivery Aspects of DNA Vaccination


Friday, January 09 | 8:00AM - 11:00AM
Delivery Systems and Mucosal Immunization
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 4
Charles J. Arntzen, Biodesign Institute, Arizona State University, USA
Plant-Derived, Heat-Stable Subunit Vaccines for Oral Immunization


Friday, January 09 | 8:00AM - 11:00AM
Delivery Systems and Mucosal Immunization
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 4
Jean-Marc Balloul, Transgene S.A., France
Antigen + Cytokine Immunotherapy for HPV-Induced Cervical Cancer


Friday, January 09 | 8:00AM - 11:00AM
Delivery Systems and Mucosal Immunization
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 4
Thomas Lehner, Guy's, King's & St. Thomas' Hospital Medical and Dental School, UK
Innate and Adaptive Mucosal Immunity in Protection Against HIV Infection


Friday, January 09 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Foyer


Friday, January 09 | 11:00AM - 1:00PM
Poster Setup
Room: Longs Peak


Friday, January 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Longs Peak


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 1 of 8
* Jean L. Patterson, Southwest Foundation for Biomedical Research, USA

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 2 of 8
Michael J. Buchmeier, University of California Irvine, USA
Antisense Morpholino Oligomers Directed Against the 5’-End of the Genome Inhibit SARS Coronavirus Proliferation and Growth

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 3 of 8
Dimiter S. Dimitrov, National Institutes of Health, USA
Cloning, Expression, Purification and Characterization of Full-Length and Soluble Fragments of the SARS-CoV S Glycoprotein

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 4 of 8
Kurt I. Kamrud, Ceva Animal Health, USA
Development of an Alphavirus Replicon Vector Vaccine for SARS-CoV

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 5 of 8
Mark J. Cameron, Toronto General Hospital, Canada
Immune Responses in Patients with Severe Acute Respiratory Syndrome (SARS): Lessons from Cytokine and Gene Expression Profiling, FACS Analysis, and Epitope Mapping

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 6 of 8
Alessandro Sette, La Jolla Institute for Immunology, USA
Human T-Cell Epitopes in SARS

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 7 of 8
Graham Simmons, University of Pennsylvania, USA
Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Encoded Spike (S) Glycoprotein Mediates Viral Entry

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: SARS
Room: Grays Peak 3

Speaker 8 of 8
Jan terMeulen, Immune Design, USA
Mapping of Human B-Cell Epitopes on all Predicted Transmembrane Proteins of the SARS-CoV and Generation of Human Monoclonal Antibodies Against the Virus

Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 8
* Liisa K. Selin, University of Massachusetts Medical School, USA
The Significance of Heterologous Immunity for Mixed Modality Vaccines


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 8
Claire L. Hutchings, University of Oxford, UK
Novel Immunization Strategies using DNA, Poxvirus and Protein Demonstrate a Widely Applicable Method for Simultaneous Induction of Potent Cellular and Humoral Immunity to the Co-Administered Protein and Encoded Antigen


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 8
Anne C. Moore, University College Cork, Ireland
Pre-Existing Fowlpox Immunity is Less Inhibitory to Heterologous Prime-Boost Vaccine Strategies Compared to Anti-MVA Immunity


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 8
Andreas Mörner, Public Health Agency of Sweden, Sweden
Immunogenicity and Protective Efficacy of Three Different Prime-Boost HIV-1/SIV Vaccine Regimens in Macaques


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 5 of 8
John Stambas, St. Jude Children's Research Hospital, USA
Robust and Long-Lived Anti-HIV Envelope Responses Following a Prime-Boost-Boost Immunization Strategy


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 6 of 8
† Markus Cornberg, University of Massachusetts Medical School, USA
Private Specificity of Epitope Specific TCR Repertoire may Determine Patterns of Cross-Reactive T-Cell Responses


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 7 of 8
Chien-Fu Hung, Johns Hopkins University, USA
Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies


Friday, January 09 | 2:00PM - 4:00PM
Workshop 3: Mixed-Modality Vaccines, and Vaccines that Targe
t Dendritic Cells
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 8 of 8
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Design of Vaccines that Regulate Dendritic Cell State and Trafficking


Friday, January 09 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Longs Foyer


Friday, January 09 | 5:00PM - 7:00PM
Immune Therapy and Immunopotentiation of Disease
Room: Grays Peak 3

Speaker 1 of 4
* Kathryn V. Holmes, University of Colorado School of Medicine, USA

Friday, January 09 | 5:00PM - 7:00PM
Immune Therapy and Immunopotentiation of Disease
Room: Grays Peak 3

Speaker 2 of 4
James D. Marks, University of California, San Francisco, USA
Recombinant Antibodies for Botulinum Neurotoxin Immunotherapy

Friday, January 09 | 5:00PM - 7:00PM
Immune Therapy and Immunopotentiation of Disease
Room: Grays Peak 3

Speaker 3 of 4
Arturo Casadevall, Albert Einstein College of Medicine, USA
Immediate Immunity for Biological Defense - The Passive Antibody Option

Friday, January 09 | 5:00PM - 7:00PM
Immune Therapy and Immunopotentiation of Disease
Room: Grays Peak 3

Speaker 4 of 4
Brent L. Iverson, University of Texas at Austin, USA
New Approaches to Antibody Engineering: An Improved Anti-PA Antibody

Friday, January 09 | 5:00PM - 7:00PM
Technologies for APC Targeting, Stimulating Specific Arms of
the Immune System
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 1 of 3
Melissa J. Robbiani (Pope), Population Council, USA
Exploiting Dendritic Cells for Improved Vaccines


Friday, January 09 | 5:00PM - 7:00PM
Technologies for APC Targeting, Stimulating Specific Arms of
the Immune System
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 2 of 3
* Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Targeting Different Antigen Processing Pathways for Biased Immune Responses


Friday, January 09 | 5:00PM - 7:00PM
Technologies for APC Targeting, Stimulating Specific Arms of
the Immune System
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 3 of 3
Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA


Friday, January 09 | 7:00PM - 8:00PM
Social Hour
Room: Longs Peak


Friday, January 09 | 7:30PM - 10:00PM
Poster Session 3
Room: Longs Peak


Saturday, January 10 | 7:00AM - 11:00AM
Breakfast
Room: Longs Peak


Saturday, January 10 | 8:30AM - 11:00AM
siRNA and Gene Silencing
Room: Grays Peak 3

Speaker 1 of 4
* Arturo Casadevall, Albert Einstein College of Medicine, USA

Saturday, January 10 | 8:30AM - 11:00AM
siRNA and Gene Silencing
Room: Grays Peak 3

Speaker 2 of 4
Carol D. Blair, Colorado State University, USA
Exploiting RNAi to Develop Arbovirus Resistance in Mosquitoes

Saturday, January 10 | 8:30AM - 11:00AM
siRNA and Gene Silencing
Room: Grays Peak 3

Speaker 3 of 4
Charles E. Samuel, University of California, Santa Barbara, USA
Interferon Action, Double-Stranded RNA, and Gene Silencing by RNA Interference

Saturday, January 10 | 8:30AM - 11:00AM
siRNA and Gene Silencing
Room: Grays Peak 3

Speaker 4 of 4
Nancy J. Sullivan, NIAID, National Institutes of Health, USA
Strategies to Inhibit Ebola Virus Infection

Saturday, January 10 | 8:30AM - 11:00AM
Lessons Learned from Diseases Requiring Stimulation of Immun
ity (Cancer, Preventive Vaccines)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 1 of 3
David B. Weiner, Wistar Institute, USA
Engineering Improved DNA Vaccine Immune Responses


Saturday, January 10 | 8:30AM - 11:00AM
Lessons Learned from Diseases Requiring Stimulation of Immun
ity (Cancer, Preventive Vaccines)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 2 of 3
* Nicholas P. Restifo, Lyell, USA
How Lymphodepletion Enhances Autoimmunity and Cancer Regression after the Adoptive Transfer of T Cells


Saturday, January 10 | 8:30AM - 11:00AM
Lessons Learned from Diseases Requiring Stimulation of Immun
ity (Cancer, Preventive Vaccines)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 3 of 3
John D. Clemens, International Vaccine Institute, South Korea
Thinking Downstream to Accelerate the Introduction of New Vaccines for Developing Countries: The Importance of Translational Research


Saturday, January 10 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Foyer


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 1 of 9
* Barry J. Beaty, Colorado State University, USA

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 2 of 9
Igor M. Belyakov, National Cancer Institute, National Institutes of Health, USA
Shared Modes of Protection against Poxvirus Infection by Attenuated and Conventional Smallpox Vaccine Viruses

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 3 of 9
Jason W. Botten, The Scripps Research Institute, USA
Identification of Human Cytotoxic T Lymphocyte Epitopes Present in Lassa Virus

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 4 of 9
Shane Crotty, La Jolla Institute for Immunology, USA
Long Term B Cell Memory in Humans after Smallpox Vaccination

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 5 of 9
Menzo J. E. Havenga, Crucell Holland BV, Netherlands
Immunogenicity of Prototype Adenovirus-Based Ebola Vaccines in the Absence and Presence of Pre-Existing Adenovirus Immunity

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 6 of 9
Malachy I. Okeke, University of Tromsø, Norway, Norway
Characterization of Recombinant Viruses Obtained by Co-Infection of BHK-21 Cells with a Live Vaccinia Virus Vectored Influenza Vaccine and a Naturally Occurring Cowpox Virus

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 7 of 9
Ted M. Ross, University of Georgia, USA
Using C3d to Enhance Immune Responses to Infectious Agents

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 8 of 9
Amy C. Shurtleff, SRI International, USA
Production and Evaluation of a DNA Vaccine Against Lassa Virus in a Guinea Pig Infection Model

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Host Responses
Room: Grays Peak 3

Speaker 9 of 9
Christina F. Spiropoulou, Centers for Disease Control, USA
Hantavirus Infection Stimulates the MAPK/ERK Signaling Pathway to Produce Proinflammatory Chemokines

Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 1 of 7
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 2 of 7
Darrell R. Galloway, Naval Medical Research Center, USA
DNA Vaccination Against Anthrax - An Update


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 3 of 7
Manisha Gupta, Centers for Disease Control, USA
Perforin is Required for Protection against Ebola Virus Infection


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 4 of 7
Karl J. Ljungberg, Karolinska Institutet, Sweden
SARS Coronavirus Inhibited by siRNA


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 5 of 7
Michael T. Rock, Vanderbilt University Medical Center, USA
Characterization of Immune Responses after Smallpox Immunization


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 6 of 7
Alessandro Sette, La Jolla Institute for Immunology, USA
Dominance in T Cell Responses to Smallpox Vaccination


Saturday, January 10 | 2:00PM - 4:00PM
Workshop 4: Vaccines and Gene-Delivery Strategies for Biodef
ense and Emerging Diseases
This session is from Vaccines/Immunotherapeutics
Room: Grays Peak 1-2

Speaker 7 of 7
Søren Buus, University of Copenhagen, Denmark
SARS CTL Vaccine Candidates; HLA Supertype-, Genome-Wide Scanning and Biochemical Validation


Saturday, January 10 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Longs Foyer


Saturday, January 10 | 5:00PM - 7:00PM
Circumventing and Directing the Immune Respone with Genetic
Engineering

Room: Grays Peak 3

Speaker 1 of 4
* Charles E. Samuel, University of California, Santa Barbara, USA

Saturday, January 10 | 5:00PM - 7:00PM
Circumventing and Directing the Immune Respone with Genetic
Engineering

Room: Grays Peak 3

Speaker 2 of 4
Joel R. Haynes, LigoCyte Pharmaceuticals, Inc., USA
Genetic Adjuvants for DNA Vaccines

Saturday, January 10 | 5:00PM - 7:00PM
Circumventing and Directing the Immune Respone with Genetic
Engineering

Room: Grays Peak 3

Speaker 3 of 4
Christopher P. Locher, Maxygen, Inc., USA
Development of a Novel Vaccines using DNA Shuffling/Screening Strategies and Bacillus Spore Display

Saturday, January 10 | 5:00PM - 7:00PM
Circumventing and Directing the Immune Respone with Genetic
Engineering

Room: Grays Peak 3

Speaker 4 of 4
R. Mark L. Buller, St. Louis University, USA
IL-4 Enhancement of Poxvirus Lethality: Implications for Small Pox

Saturday, January 10 | 5:00PM - 7:00PM
Lessons Learned from Diseases Requiring Altering Immunity (A
utoimmunity, Allergy)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 1 of 3
* Lawrence Steinman, Stanford University, USA
Reverse Genomics: Protein Microarrays Guide Tolerizing DNA Vaccine Treatment of Autoimmune Diseases


Saturday, January 10 | 5:00PM - 7:00PM
Lessons Learned from Diseases Requiring Altering Immunity (A
utoimmunity, Allergy)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 2 of 3
Gabriel Nussbaum, Hebrew University of Jerusalem, Israel
HSP60 Peptide Treatment of Autoimmune Diabetes


Saturday, January 10 | 5:00PM - 7:00PM
Lessons Learned from Diseases Requiring Altering Immunity (A
utoimmunity, Allergy)
This session is from Vaccines/Immunotherapeutics

Room: Grays Peak 1-2

Speaker 3 of 3
Eyal Raz, University of California, San Diego, USA
Probiotics for Inflammatory Bowel Disease: Mystery Unfolding


Saturday, January 10 | 7:00PM - 8:00PM
Social Hour
Room: Longs Peak


Saturday, January 10 | 8:00PM - 11:00PM
Entertainment
Room: Longs Peak


Saturday, January 10 | 8:00PM - 11:00PM
Cash Bar
Room: Longs Peak


Sunday, January 11 | 10:21AM - 10:21AM
Departure


*Session Chair
†Invited, not yet responded.